Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7592)
All Articles published online
|
Publishing Process of This Article
|
May 24, 2019 (publication date) through Jan 13, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Meghal T, Dave V, Tang H, Kumar V, Xu Y. Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. World J Clin Oncol 2019; 10(5): 201-212 [PMID: 31205865 DOI: 10.5306/wjco.v10.i5.201] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Meghal T, Dave V, Tang H, Kumar V, Xu Y. Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. World J Clin Oncol 2019; 10(5): 201-212 [PMID: 31205865 DOI: 10.5306/wjco.v10.i5.201] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v10/i5/201.htm |
| Number | Citing Articles |
| 1 |
Geng Li, Mohammad Massumi, Hajar Owji, Ge Yang, Eugenia Girda, Arash Hatefi. Engineered tumor-tropic mesenchymal stem cells as targeted therapeutic delivery systems for refractory Ovarian cancer. Journal of Controlled Release 2026; 390: 114584 doi: 10.1016/j.jconrel.2025.114584
|